Financial Performance - Revenue increased by 24.9% to approximately HK$1,793.0 million for the year ended 31 December 2022, compared to approximately HK$1,435.8 million for the previous year[22]. - Gross profit margin increased by 4.9 percentage points to 23.7% for the year ended 31 December 2022, up from 18.8% in the previous year[23]. - Profit attributable to owners of the Company was approximately HK$75.5 million for the year ended 31 December 2022, a significant recovery from a loss of approximately HK$93.5 million in the previous year[24]. - Gross profit increased by 57.6% to approximately HK$424.8 million for the year ended December 31, 2022, compared to approximately HK$269.6 million for the previous year[37]. - Operating profit was approximately HK$91.8 million, a significant recovery from an operating loss of approximately HK$92.4 million in the prior year[38]. - Total revenue rose by 24.9% to approximately HK$1,793.0 million, up from approximately HK$1,435.8 million in the previous year[57]. - The Group recorded a revenue of approximately HK$1,793.0 million for the year ended 31 December 2022, representing a 24.9% increase compared to HK$1,435.8 million for the year ended 31 December 2021[70]. - Gross profit for the year ended 31 December 2022 was approximately HK$424.8 million, a 57.6% increase from HK$269.6 million for the year ended 31 December 2021[70]. - Profit attributable to owners of the Company for the year ended 31 December 2022 was approximately HK$75.5 million, compared to a loss of approximately HK$93.5 million for the year ended 31 December 2021[70]. - Basic and diluted earnings per share attributable to owners of the Company for the year ended 31 December 2022 were HK10.4 cents, compared to a loss of HK12.8 cents per share in the prior year[85]. Revenue Breakdown - The hotel supplies business generated revenue of approximately HK$1,376.9 million, accounting for 76.8% of total revenue, while health care and hygiene products contributed approximately HK$266.7 million, or 14.9%[57]. - The hospitality supplies business contributed approximately HK$1,376.9 million, while the OS&E business and health care products contributed HK$149.4 million and HK$266.7 million, respectively, for the year ended 31 December 2022[70]. - Revenue from the health care and hygienic products business segment generated approximately HK$266.7 million for the year ended December 31, 2022, an increase from HK$191.3 million in the previous year, representing 14.9% of total revenue[134]. - Revenue from the health care and hygienic products business for the year ended December 31, 2022, was approximately HK$266.7 million, a 39.4% increase from approximately HK$191.3 million in 2021, contributing 14.9% to the Group's total revenue[162]. - Revenue from Hong Kong's health care and hygienic products business was approximately HK$77.7 million in 2022, up from approximately HK$51.9 million in 2021, representing 29.1% of the total revenue from this segment[177]. Dividends - The proposed final dividend for the year ended 31 December 2022 is HK$0.03 per share, with a total dividend of HK$0.04 per share for the year, representing a payout ratio of 38.5%[27]. - A proposed final dividend of HK3.0 cents per share was recommended, alongside an interim dividend of HK1.0 cent per share, resulting in a total dividend of HK4.0 cents per share and an annual payout ratio of 38.5%[39]. - The Board proposed a final dividend of HK3.0 cents per share for the year ended December 31, 2022, with total expected dividends of HK4.0 cents per share[85]. Business Strategy and Outlook - The Group plans to continue investing in product research and development to enhance capabilities and meet changing market demands[6]. - The Group aims to expand its business scope in health care and hygienic products to enhance brand penetration and operational efficiency[6]. - The Group is optimistic about future prospects in the health care products industry and will adjust marketing strategies to enhance business development opportunities[6]. - The Group plans to adopt advanced technology for the research and development of health care and hygiene products to meet growing market demand[48]. - The Group aims to optimize its product mix and enhance competitiveness to capture market opportunities and improve business performance[49]. - The Group anticipates a recovery in global tourism, projecting a 30% increase in international tourist arrivals in 2023, reaching 1.6 billion[143]. - The Group's strategy includes developing the Southeast Asia market to capitalize on the recovery of the tourism sector[144]. - The Group plans to explore potential demand in the operating supplies and equipment market and expand its replenishment business scale to enhance customer loyalty[133]. Asset and Equity Position - Total assets as of 31 December 2022 were approximately HK$1,749.5 million, with total equity of approximately HK$1,131.5 million[29]. - The Group's cash and cash equivalents as of December 31, 2022, amounted to approximately HK$305.4 million, an increase from approximately HK$251.2 million as of December 31, 2021[85]. - The Group's net assets as of December 31, 2022, were approximately HK$1,131.5 million, compared to HK$1,094.4 million as of December 31, 2021[85]. Market Conditions and Risks - The outlook for the global tourism industry remains cautiously optimistic, with recovery dependent on economic and public health factors[49]. - The domestic economy and tourism industry in China are expected to improve following the lifting of entry restrictions, positively impacting the company's hotel supplies business[51]. - The global tourism recovery is reflected in the increase of international tourists to over 900 million in 2022, which is double the number recorded in 2021[128]. - The easing of COVID-19 restrictions has positively impacted the demand for hospitality supplies, contributing to the overall revenue growth[128]. - The Group is exposed to foreign exchange risk primarily with respect to Renminbi (RMB) and does not currently deploy a foreign currency hedging policy[100]. Corporate Governance - The Company emphasizes high standards of corporate governance practices, focusing on accountability and transparency[196]. - The Board reviews its corporate governance practices periodically to meet rising shareholder expectations[196]. - The Group complied with all code provisions in the "Corporate Governance Code" except for certain deviations[197].
明辉国际(03828) - 2022 - 年度财报